Provided by Tiger Trade Technology Pte. Ltd.

Mineralys Therapeutics, Inc.

23.68
+0.07000.30%
Post-market: 23.680.00000.00%19:49 EDT
Volume:1.44M
Turnover:34.18M
Market Cap:1.95B
PE:-10.34
High:24.22
Open:23.42
Low:23.30
Close:23.61
52wk High:47.65
52wk Low:10.44
Shares:82.40M
Float Shares:60.57M
Volume Ratio:1.04
T/O Rate:2.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2900
EPS(LYR):-2.2900
ROE:-36.91%
ROA:-24.58%
PB:3.02
PE(LYR):-10.34

Loading ...

Mineralys Therapeutics Shares Fall Following Executives' Stock Sale

MT Newswires Live
·
Nov 15, 2025

Mineralys Therapeutics falls -13.9%

TIPRANKS
·
Nov 14, 2025

Mineralys Therapeutics Director Daphne Karydas Reports Disposal of Common Shares

Reuters
·
Nov 14, 2025

Evercore ISI Keeps Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

TIPRANKS
·
Nov 12, 2025

Stock Track | Mineralys Therapeutics Soars 5.22% as Multiple Analysts Raise Price Targets

Stock Track
·
Nov 11, 2025

Stifel Nicolaus Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS)

TIPRANKS
·
Nov 11, 2025

LifeSci Capital Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

TIPRANKS
·
Nov 11, 2025

Wells Fargo Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

TIPRANKS
·
Nov 11, 2025

Mineralys Therapeutics, Inc. : Wells Fargo Raises Target Price to $55 From $50

THOMSON REUTERS
·
Nov 11, 2025

Mineralys Therapeutics files automatic mixed securities shelf

TIPRANKS
·
Nov 11, 2025

Mineralys Therapeutics Inc - in Addition, Offering of up to $300 Mln of Common Stock

THOMSON REUTERS
·
Nov 11, 2025

Mineralys Therapeutics Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
Nov 11, 2025

Earnings Flash (MLYS) Mineralys Therapeutics Posts Q3 Loss $0.52, vs. FactSet Est of $0.61 Loss

MT Newswires Live
·
Nov 11, 2025

Mineralys Therapeutics Q3 net loss narrows

Reuters
·
Nov 11, 2025

BRIEF-Mineralys Therapeutics Q3 EPS USD -0.52

Reuters
·
Nov 11, 2025

Mineralys Therapeutics (MLYS): Assessing Valuation Following Positive Phase 3 Results for Lorundrostat and FDA Filing Plans

Simply Wall St.
·
Nov 09, 2025

Why Mineralys Therapeutics (MLYS) Is Up After Positive Phase 3 Lorundrostat Data and FDA Filing Plans

Simply Wall St.
·
Nov 08, 2025

Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025

GlobeNewswire
·
Nov 03, 2025

BRIEF-Sunoco LP Announces Results of Early Participation in Private Exchange Offers and Consent Solicitations for Outstanding Notes of Parkland Corporation and Extension of the Early Participation Exchange Consideration

Reuters
·
Oct 21, 2025

Mineralys Therapeutics CEO Jon Congleton Reports Disposal of Common Shares

Reuters
·
Oct 16, 2025